Insider Transaction: ResMed Counsel divests minor stake under 10b5-1

Rhea-AI Filing Summary

ResMed Inc. (RMD) Form 4: Global General Counsel & Secretary Michael J. Rider reported a modest open-market sale of company stock.

• Transaction: On 01 Aug 2025 he sold 50 common shares at $281.90 each, generating roughly $14.1k in gross proceeds. The sale was carried out under a pre-arranged Rule 10b5-1 plan adopted 28 Feb 2025.
• Post-sale holdings: Rider now directly owns 8,486 shares; no derivative positions were reported.

The divestiture represents an immaterial decrease in the executive’s stake and an insignificant fraction of ResMed’s total float, suggesting limited market impact. Because the trade was executed under a 10b5-1 plan, timing-related information asymmetry concerns are mitigated. Investors may view the filing as routine but should track subsequent insider activity for trend changes.

Positive

• Trade executed under Rule 10b5-1, indicating pre-planned compliance and reducing concerns of opportunistic selling.

Negative

• Insider sale, albeit small, could be interpreted cautiously by risk-averse investors monitoring executive sentiment.

Insights

Equity Research Analyst

TL;DR: 50-share sale by ResMed’s GC is de minimis, executed under 10b5-1; neutral signal for shareholders.

The transaction involves approximately US$14k, reducing Rider’s direct stake to 8,486 shares. That is inconsequential relative to ResMed’s ~148 m shares outstanding and does not hint at strategic concerns. Rule 10b5-1 automation further diminishes informational value. From a governance lens, ongoing transparency is positive, yet the size and context render the event non-impactful to valuation or sentiment. Rating: neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rider Michael J

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	08/01/2025		S(1)		50	D	$281.9	8,486	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025.

	Michael J. Rider, Global General Counsel and Secretary	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who conducted the insider sale disclosed in ResMed (RMD) Form 4?

Global General Counsel & Secretary Michael J. Rider.

How many ResMed shares were sold and at what price?

Rider sold 50 shares at $281.90 per share on 01 Aug 2025.

How many shares does the insider still own after the transaction?

He now holds 8,486 ResMed common shares directly.

Was the transaction under a Rule 10b5-1 trading plan?

Yes, the plan was adopted on 28 Feb 2025.

Does this filing signal a major change in ResMed’s outlook?

Given the small size and pre-planned nature, it is generally considered non-material to the company’s outlook.

Are any derivative securities involved in this Form 4?

No derivative transactions were reported in the filing.